From the gut to the brain: Potential novel avenues for IBD treatment via serotonergic pathways

Approximately 6.8 million people globally are affected by inflammatory bowel disease (IBD), which is associated with dysbiosis in the gut microbiota.

• IBD is characterized by chronic relapsing intestinal inflammation, with Crohn's disease and ulcerative colitis as its main forms.
• Dysbiosis in the gut microbiota is linked to the onset of IBD.
• Current treatments for IBD provide anti-inflammatory effects but may lead to immunosuppression and increased risk of comorbidities.
• The gut-brain axis facilitates communication between the gut and the brain through various signaling pathways.
• Dysbiosis, neuroinflammation, and serotonergic dysregulation may be interconnected factors contributing to the pathogenesis of IBD and related neurological issues.
• The serotonergic signaling pathway is proposed as a potential novel therapeutic target for combination therapy in IBD.

AI simplified